

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D. *et al.*

Serial No.: **10/565,713**

Filed: 25 January 2006

Title: SUBSTITUTED 2-AMINOTETRALIN FOR THE TREATMENT OF DEPRESSION

Group Art Unit: 1627

Examiner: U. Ramachandran

Confirmation No.: 7929

Docket No.: **6102-000008/US/NP**

Client Ref.: P/Sche/II/5/03

SUBMITTED ELECTRONICALLY VIA EFS-WEB

11 August 2011

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

LETTER TO EXAMINER

Applicant filed a Supplemental Information Disclosure Statement on 19 July 2011 ("19 July 2011 IDS") with the USPTO. In the 19 July 2011 IDS, Applicant cited and provided abstracts for the following:

1. Beaulieu, et al., "N,N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists" European Journal of Pharm., Oct 1984, vol. 105, pp. 15-21 (Beaulieu);
2. Belluzzi, et al., "N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's" Mov. Dis., Mar 1994, 9:2, pp 937-946 (Belluzzi); and
3. Muscat, et al., "Antidepressant-like effects of dopamine agonists in an animal model of depression" Bio Psychiatry, May 1992, Vol. 31, Issue 9, pp 937-946 (Muscat).

Applicant encloses with this letter the full text journal articles of Beaulieu, Belluzzi, and Muscat. Applicant also includes the 19 July 2011 Form 1449, with "abstract" removed from Beaulieu, Belluzzi, and Muscat (p. 1).

Serial No. 10/565,713

6102-000008/US/NP

Letter to Examiner

11 August 2011

Consideration by the Examiner of the present submission is requested.

Should any issue remain, the Examiner is invited to call the undersigned at the telephone number given below.

HARNESS, DICKEY & PIERCE, P.L.C.

/ Molly B. Edwards /

Molly B. Edwards
Attorney for Applicant
Reg. No. 68,013
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
314.446.7682 (direct)
314.726.7501 (fax)

Attachments

Full text journal articles of Beaulieu, Belluzzi, and Muscat

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 2	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000008/US/NP	10/565,713
	APPLICANT	
	Scheller, D. <i>et al.</i>	
	FILING DATE	GROUP
	25 January 2006	1627

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		2005/0037983	02-17-2005	Dinan	A61K 31/7048	03-11-2004
		2005/0038015	02-17-2005	Bronzova, et al.	A61K 31/551	02-11-2003
		4,769,028	09-06-1988	Hoffmann, et al.	A61K 9/70	07-17-1986

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	Translation No

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
		Beaulieu, et al., "N,N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists" <i>European Journal of Pharm.</i> , Oct 1984, vol. 105, pp. 15-21 (Abstract)
		Belluzzi, et al., "N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's" <i>Mov. Dis.</i> , Mar 1994, 9:2, pp 937-946 (Abstract)
		Bertaine-Anglade, V., et al. (2006) "Antidepressant properties of Rotigotine in experimental models of depression," <i>European Journal of Pharmacology</i> . 548: 106-114
		Corrigan, et al., "Comparison of Pramipexole, Fluoxetine, and Placebo in Patients with Major Depression" <i>Depression and Anxiety</i> , 2000, Vol. 11, 58-65 (Abstract)
		Goetz, G., et al. (2003) "The Unified Parkinson's Disease Rating Scale (UPDRS): Status and Recommendations," <i>Movement Disorders</i> . 18 (7): 738-750
		Muscat, et al., "Antidepressant-like effects of dopamine agonists in an animal model of depression" <i>Bio Psychiatry</i> , May 1992, Vol. 31, Issue 9, pp 937-946 (Abstract)
		Rotigotine (Transdermal Route) (2007) http://www.mayoclinic.com/health/drug-information/DR602471/DSECTION=proper-use . Pg 1-8
		Scheller, D., et al. (2009) "The in vitro receptor profile of Rotigotine: a new agent for the treatment of Parkinson's disease," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> 379: 73-86
		Wang, W., et al. (2007) "Effects of Apomorphine on the Expression of Learned Helplessness Behavior," <i>Chinese Journal of Physiology</i> . 50 (2): 63-68

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 2	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000008/US/NP	10/565,713
	APPLICANT	
	Scheller, D. <i>et al.</i>	
	FILING DATE	GROUP
25 January 2006	1627	

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
		http://en.wikipedia.org/wiki/Apomorphine (printed 6 June 2011)
		Office Action, dated November 1, 2002 issued in U.S. Application No.09/647,290
		Office Action, dated September 13, 2007 issued in U.S. Application No.10/936,620
		Office Action, dated May 1, 2008 issued in U.S. Application No.10/936,620
		Office Action, dated October 16, 2008 issued in U.S. Application No.10/587,637
		Office Action, dated January 26, 2009 issued in U.S. Application No.10/936,620
		Office Action, dated September 2, 2009 issued in U.S. Application No.10/587,637
		Office Action, dated October 23, 2009 issued in U.S. Application No.10/565,699
		Office Action, dated November 6, 2009 issued in U.S. Application No.10/936,620
		Office Action, dated May 27, 2010 issued in U.S. Application No.10/565,699
		Office Action, dated June 7, 2010 issued in U.S. Application No.10/587,637
		Office Action, dated October 8, 2010 issued in U.S. Application No.10/936,620
		Office Action, dated February 14, 2011 issued in U.S. Application No.10/565,699

60843808.1

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.